

Applicants: Ann Marie Schmidt, et al.
U.S. Serial No.: 10/783,635
Filed: February 20, 2004
Page 2

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

1-48. (Canceled)

49. (Currently Amended) A method for ~~inhibiting the interaction of an advanced glycation endproduct (AGE) with a receptor for advanced glycation endproduct (RAGE) in~~ treating a subject suffering from kidney failure, systemic lupus erythematosus, inflammatory lupus nephritis or amyloidoses, which comprises administering to the subject an amount of quinine or quinidine ~~or a derivative thereof~~ effective to inhibit the interaction between the AGE and RAGE in the subject, so as to thereby treat the subject.

50-57. (Canceled)

58. (Currently Amended) The method of claim ~~32~~ 49, wherein the subject is a human, a primate, ~~a mouse, a rat or a dog~~ an equine subject, an opine subject, an avian subject, a bovine subject, a porcine subject, a canine subject, a feline subject, or a murine subject.

59. (Currently Amended) The method of claim ~~32~~ 49, wherein the administration comprises intralesional, intraperitoneal, intramuscular or intravenous injection; infusion; liposome-mediated delivery; or topical, nasal, oral, ocular or otic delivery.

Applicants: Ann Marie Schmidt, et al.
U.S. Serial No.: 10/783,635
Filed: February 20, 2004
Page 3

60. (Currently Amended) The method of claim ~~32~~ 49, wherein the compound is administered hourly, daily, weekly, monthly or annually.
61. (Currently Amended) The method of claim ~~32~~ 49, wherein the effective amount of ~~the compound~~ quinine or quinidine comprises from about 0.000001 mg/kg body weight to about 100 mg/kg body weight.
62. (Currently Amended) The method of claim ~~32~~ 49, wherein the subject is suffering from kidney failure.
63. (Canceled)
64. (Currently Amended) The method of claim ~~32~~ 49, wherein the subject is suffering from systemic lupus erythematosus ~~or inflammatory lupus nephritis~~.
65. (Currently Amended) The method of claim ~~32~~, 49, wherein the subject is ~~an obese subject~~ suffering from obesity.
66. (Currently Amended) The method of claim ~~32~~ 49, wherein the subject is an aged subject.
67. (Currently Amended) The method of claim ~~32~~ 49, wherein the subject is suffering from amyloidoses.
68. (Canceled)
69. (Currently Amended) The method of claim ~~32~~ 49, further

comprising administering to the subject a pharmaceutically acceptable carrier during the administration of the compound.

70. (Previously Presented) The method of claim 69, wherein the carrier comprises a diluent.
71. (Previously Presented) The method of claim 69, wherein the carrier comprises a virus, a liposome, a microencapsule, a polymer encapsulated cell or a retroviral vector.
72. (Previously Presented) The method of claim 69, wherein the carrier is an aerosol, intravenous, oral or topical carrier.
73. (Previously Presented) The method of claim 69, wherein the compound is administered from a time release implant.
- 74-75. (Canceled)
76. (New) The method of claim 49, wherein the subject is suffering from inflammatory lupus nephritis.
77. (New) The method of claim 49, which comprises administering to the subject an amount of quinine.
78. (New) The method of claim 49, which comprises administering to the subject an amount of quinidine.